Video Library

In this last batch of the Q&A Session of Blood Cancer OncTalk, Drs. Aaron Goodman, Sridevi Rajeeve, Tycel Phillips, Alakrita Taneja, and Marco Ruiz come together to answer questions from the attendees at our Blood Cancer OncTalk 2023 live event. To watch the complete playlist click here.

In this first batch of the Q&A Session of Blood Cancer OncTalk, Drs. Aaron Goodman, Sridevi Rajeeve, Tycel Phillips, Alakrita Taneja, and Marco Ruiz come together to answer questions from the attendees at our Blood Cancer OncTalk 2023 live event. To watch the complete playlist click here.

This is the third batch of videos from the Blood Cancer OncTalk playlist. In these videos, Dr. Alankrita Taneja defines Smoldering Multiple Myeloma (SMM) and discusses how it differs from Multiple Myeloma (MM), risk factors and treatments. To watch the complete playlist click here.

This is the third batch of videos from the Blood Cancer OncTalk playlist. In these videos, Dr. Sridevi Rajeeve gives a brief description of multiple myeloma, and how immunotherapy is used in treatment. To watch the complete playlist click here.

This is the first batch of videos from the Blood Cancer OncTalk playlist. In these videos, Dr. Tycel Phillips discusses Bispecific Antibody Treatment in Non-Hodgkin Lymphoma: Epcoritamab Glofitamab To watch the complete playlist click here.

This is the second batch of videos from the Blood Cancer OncTalk playlist. In these videos, Dr. Marco Ruiz explains the concept of bone marrow transplant, and how it is used in treating blood cancers. Myeloma Lymphoma To watch the complete playlist click here.

This is the third batch of videos from the Blood Cancer OncTalk playlist. In these videos, Dr. Sridevi Rajeeve gives a brief description of multiple myeloma, and how immunotherapy is used in treatment. To watch the complete playlist click here.

Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the genetic risk (or lack thereof) for lung cancer.

Radiation therapy can be very helpful in treating painful bone metastases or those at risk for causing a fracture due to compromise of bone strength. Dr. Vivek Mehta reviews the basics of this approach. Please feel free to offer comments and raise questions in our Discussion Forums. Transcript

Transcript One of the important points about patients with advanced lung cancer is that 30-40% of patients will develop bone metastases. I think it’s important to recognize this is not bone cancer, this is lung cancer that’s moved to the bone, and in 30-40% of patients at some point who have

Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.

UCLA Med Center's Dr. Eddie Garon discusses the open question of the optimal duration of ongoing treatment with immunotherapy for lung cancer.

Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely to use these agents instead of or in combination with standard chemotherapy soon.

Dr. Jeffrey Bradley, Radiation Oncologist at Washington University in St. Louis, defines oligometastatic lung cancer and describes the recent trend toward the use of stereotactic body radiation therapy to treat it.

Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.